Publications by authors named "S M Podos"

Claim this Profile
F
First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated Diseases.
Venkat R Gadhachanda, Jason A Wiles, Steven D Podos, David Boyer, Jane Thanassi

Pharm Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated Diseases.
Venkat R Gadhachanda, Jason A Wiles, Steven D Podos, David Boyer, Jane Thanassi

Pharm Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Steven D Podos, Howard Trachtman, Gerald B Appel, Andrew S Bomback, Bradley P Dixon

Am J Nephrol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Carla Nester, Gerald B Appel, Andrew S Bomback, Koenraad Peter Bouman, H Terence Cook, Steven D Podos

Am J Nephrol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies.
David D Boyer, Ya-Ping Ko, Steven D Podos, Mark E Cartwright, Xiang Gao

Transl Vis Sci Technol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis